Clinical Resources for Clinicians · For clinicians

Von Willebrand Disease in Pregnancy: Antenatal and Delivery Planning

By the Find Her Doctor editorial team · Updated November 1, 2026 · 6 min read

Von Willebrand disease in pregnancy needs a written plan agreed by obstetrics, hematology and anesthesia by about 32–34 weeks. Check VWF activity, VWF antigen and factor VIII in the third trimester. The 2021 ASH ISTH NHF WFH guideline suggests a VWF activity target of 0.50–1.50 IU/mL for neuraxial anesthesia, and postpartum tranexamic acid for type 1 VWD and low VWF. Levels fall quickly after delivery, so plan for delayed postpartum hemorrhage as well as immediate bleeding.

The usual failure mode isn't clinical uncertainty. It's a good plan that lives in a hematology note nobody on L&D can find at 3 a.m., a third-trimester level that was never drawn, or a patient discharged on day two with no tranexamic acid and no idea that bleeding at day ten is a reason to come back. Each of those is preventable.

How pregnancy changes VWF

VWF and factor VIII rise progressively, mainly in the second and third trimesters. What that means depends on type:

Levels drift back toward baseline over days to weeks after delivery, which is why VWD is associated with delayed (secondary) postpartum hemorrhage.

Preconception and early pregnancy

• Confirm the diagnosis and type with hematology. Many patients carry a "possible VWD" label from testing that was never finished. See the HMB bleeding-disorder workup.
• Desmopressin responsiveness: if a trial was done before pregnancy, record the result. Desmopressin in pregnancy and at delivery is individualized because of hyponatremia risk and must be hematology-directed.
• Genetic counseling: most VWD is autosomal dominant; type 3 and some type 2 variants follow other patterns. Plan neonatal testing and care accordingly.
• Iron status: many patients with VWD start pregnancy iron-deficient after years of heavy menstrual bleeding. Check ferritin at the first visit and treat. See iron deficiency screening in pregnancy.

Antenatal procedures and early bleeding

Miscarriage management, CVS, amniocentesis and cerclage may each need a hemostatic plan depending on type and current levels. Coordinate with hematology before planned procedures, and put early-pregnancy bleeding in the patient's emergency plan. If she presents to an outside ED with first-trimester bleeding, the plan is what tells them she isn't a routine threatened miscarriage.

Third-trimester assessment

• Measure VWF activity, VWF antigen and factor VIII at about 32–34 weeks, or per the hematologist's plan, and use those results for delivery planning.
• Platelet count for type 2B.
• Write the delivery plan and make it visible in the EHR and the L&D record: neuraxial eligibility, factor or desmopressin use, tranexamic acid and the neonatal plan.
• Confirm the delivering hospital can supply VWF-containing concentrate around the clock, if it might be needed. For patients planning to deliver at a smaller community unit, this is the moment to discuss whether a hospital with on-site hematology is the better choice.

Neuraxial anesthesia

The 2021 ASH ISTH NHF WFH management guideline makes a conditional recommendation, based on very low certainty evidence, to target a VWF activity level of 0.50–1.50 IU/mL rather than above 1.50 IU/mL to allow neuraxial anesthesia.

How that plays out:

• Patients with type 1 VWD whose third-trimester levels exceed 0.50 IU/mL are often eligible without treatment, after hematology and anesthesia review.
• Patients below that level may receive VWF-containing concentrate to reach target, timed to the procedure.
• Remove the catheter while levels are still adequate, because they fall after delivery. Put the removal criteria in the plan so the overnight anesthesia team isn't reconstructing it.
• When levels can't be corrected, avoid neuraxial techniques and plan alternative analgesia, ideally discussed with the patient antenatally rather than in active labor.

Thrombocytopenia from type 2B needs separate consideration. The SOAP 2021 platelet thresholds were developed for gestational thrombocytopenia, ITP and hypertensive disorders, not VWD. See thrombocytopenia in pregnancy.

Intrapartum care

• Mode of delivery follows obstetric indications. VWD alone isn't an indication for cesarean.
• Avoid, where feasible, fetal scalp electrodes, fetal blood sampling and difficult operative vaginal delivery (especially mid-cavity or rotational instruments) when the fetus may be affected. This matters most when the fetus could have type 2 or type 3 disease.
• Active management of the third stage and quantitative blood loss measurement, per ACOG PB 183.
• Factor concentrate for patients below target, given under hematology direction and available in the hospital before admission.
• Cesarean: perioperative VWF and FVIII targets are set by hematology.

Postpartum

Tranexamic acid. ASH 2021 suggests postpartum tranexamic acid for type 1 VWD or low VWF levels, and notes it may also apply to types 2 and 3. Dosing and duration follow the hematology plan; some regimens continue for up to about two weeks. This covers the window when falling VWF meets ongoing lochia. Make sure the prescription is filled before discharge, not left for the patient to pick up later with a newborn in tow.

Factor replacement. Patients who received factor for delivery may need continued replacement for several days, with levels monitored.

Delayed bleeding education. Before discharge, tell the patient plainly:

• Bleeding that soaks a pad in an hour, large clots, or a sudden increase in bleeding days or weeks after birth needs urgent evaluation.
• Bring the bleeding-disorder plan or card to any ED visit.
• Avoid NSAIDs for pain unless hematology approves them. Many patients reach for ibuprofen by default, and many discharge order sets include it, so check.

Iron. Postpartum anemia is common. Check hemoglobin and treat iron deficiency with oral or IV iron. See postpartum anemia management.

Contraception and future menses. Discuss options that reduce menstrual loss, such as the LNG-IUD or hormonal methods, as part of postpartum contraception counseling.

Neonatal considerations

• Notify pediatrics before delivery.
• Newborn VWD testing is often deferred because neonatal levels are physiologically raised. Type 3, and type 2 when the fetus is at risk, may justify early testing.
• If the infant may have significant disease, agree the plan for vitamin K administration and the timing of any circumcision with pediatric hematology. In families who plan a ritual circumcision on day eight, raise this early in the third trimester so there's time to coordinate.

A one-page delivery plan

It should fit on one page that L&D can read in under a minute:

• Diagnosis: VWD type, baseline levels and date of diagnosis
• Third-trimester levels: VWF activity, VWF antigen, FVIII and platelets (type 2B), with dates
• Neuraxial: eligible or not, conditions, catheter removal timing
• Hemostatic treatment: product, dose and timing for delivery, or "none required" with criteria for reassessment
• Avoid: for example NSAIDs, or specific instrumental approaches
• Postpartum: tranexamic acid regimen and duration, factor continuation, monitoring
• Neonatal: testing plan and pediatric notification
• Contacts: hematology on-call and the primary hematologist

Give the patient a copy and file it where the inpatient team will look on admission. If she might deliver at a different hospital than planned, which happens often enough in a city where people go into labor across a bridge from their own hospital, the copy in her bag matters.

Unrecognized VWD

Some patients are diagnosed only after an unexplained postpartum hemorrhage. Because VWF is raised in pregnancy and the early postpartum period, testing right after the event can be falsely reassuring. Plan definitive testing after recovery, once levels are back to baseline, and document the bleeding history for the next pregnancy.

Afterward, share the outcome with hematology (blood loss, treatment given, any delayed bleeding) so the next pregnancy's plan starts from real data.

Referral partnership in New York

A third-trimester VWF level, a clear neuraxial plan and a postpartum tranexamic acid prescription prevent most VWD delivery problems, and each needs hematology involvement. Premier Hematology & Oncology, which sponsors our professional resources, offers referral pathways and co-management for bleeding disorders in pregnancy, along with fast-track IV iron scheduling for patients with iron deficiency. See our hematology partners page.

Frequently asked questions

Sources

• ASH ISTH NHF WFH — 2021 guidelines on the management of von Willebrand disease
• ASH ISTH NHF WFH — 2021 guidelines on the diagnosis of von Willebrand disease
• ACOG — Postpartum Hemorrhage (Practice Bulletin No. 183)
• ACOG — Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women (Committee Opinion No. 557)
• SOAP — Interdisciplinary Consensus Statement on Neuraxial Procedures in Obstetric Patients With Thrombocytopenia (2021)

This article is for general education and is not medical advice. It does not replace an evaluation by a licensed clinician who knows your history. If you think you have a medical emergency, call 911.